Bromocriptine

The participants were recruited from a previous cross-sectional study of newly-delivered male infants and their mothers (n = 872), conducted in 2002–2003 (Longnecker et al. 2007 (link); Romano-Riquer et al. 2007 (link)). Because the objective of that study was to evaluate antiandrogenic effects of DDE, only boys were recruited. In the previous study, women were enrolled during the postpartum period at both of the city’s hospitals, which also serve the surrounding areas. Exclusion criteria for the mother included the following: age > 35 years; preeclampsia or pregnancy-related diabetes or hypertension; seizure disorders requiring daily medication; use of cortico-steroids; history of psychiatric, kidney, or cardiac disease or repeated urinary tract infections; and non-Spanish speaker. Infants were excluded if gestational age at delivery, as estimated by the Capurro scale (Capurro et al. 1978 (link)) or the medical record (based on last menstrual period), was < 36 weeks, birth weight was < 2,500 g, pregnancy was not singleton, Apgar score at 5 min was ≤ 6, or child required intensive care. The previous study included questionnaires, anthropometry, and collection of maternal serum for the measurement of DDT and DDE.
We conducted a follow-up study of these subjects to determine length of lactation. Mother–son pairs were eligible if they were enrolled in the cross-sectional study, the child was not given up for adoption (n = 1), and the mother had not used medications that inhibit or increase milk production, including contraceptive pills with estrogens, bromocriptine, or metoclopramide (n = 6). Eligible mothers were invited to participate and gave informed consent before participation in the study. The study protocol was reviewed and approved by the institutional review boards at the Instituto Nacional de Salud Pública in México and the National Institute of Environmental Health Sciences in the United States.
Of those who were eligible (n = 865), 90.6% (n = 784) were followed. Of the remaining 81 (9.4%), for 10 subjects the recorded address did not exist, for 59 the address was found but the mother was not, for 4 the mother or father refused to participate, and for 8 the mother or child had died.
Follow-up started on 20 January 2004. At that time, the ages of the babies were 3.3 to 25.1 months (median, 13.2). For children already weaned at the first visit, we recorded the duration of lactation. For those still being breast-fed, we continued home visits approximately every 2 months until the child was weaned.
The schedule of visits varied across the participants for logistical reasons. The median age at the first visit was 15.7 months (25th and 75th percentiles, 11.6 and 21.6 months). The number of visits ranged from 1 to 7 (median, 3), and the time between visits ranged from 0.8 to 11.4 months (median, 2.2). The interval from weaning until the next study visit (i.e., the recall period for duration of lactation) had a median of 7.4 months (quartiles, 2.4 and 14.1).

The experimental design for bromocriptine administration was similar to sleeve gastrectomy, namely the WSD and GKSD groups (Figure 5A). A group of GK rats (GKHCD; n = 18) was fed the same high-caloric diet between 1 and 6-months-old. At 5 months old, the HCD-fed group was randomly divided into three groups (n = 6): the first without further treatment (GKHCD); HCD rats treated with bromocriptine in the last month (GKHCD_Br), and HCD rats treated with a vehicle DMSO solution during the same period (GKHCD_Vh) [12 (link)]. Bromocriptine, gently supplied by Generis^®, (Amadora, Portugal) was diluted 1:4 DMSO/H2O and administered daily by intraperitoneal (i.p.) injection (10 mg/Kg/day) during the last month. In the vehicle group, the same volume (100 μL) of the vehicle 1:4 DMSO/H2O was administered i.p. during the same period.